Human study identifies bile-acid markers of CYP3A inhibition

Untargeted Metabolomics Reveal New Endogenous Plasma Biomarkers Associated with CYP3A Inhibition in Humans.

Clinical pharmacology and therapeutics β€’ β€’ Moderately Relevant
πŸ€–

AI Summary

The study asked whether changes in blood metabolites could reveal new markers of CYP3A activity, an enzyme involved in drug metabolism. In a fixed-sequence drug-interaction study, 11 healthy volunteers received itraconazole, which inhibits CYP3A. Untargeted metabolomics identified 58 plasma metabolites that changed significantly. Bile acids were the most prominently affected group, and targeted analysis found that GHCA, GUDCA, and conjugates of 1Ξ²OH-DCA showed roughly 10-fold lower plasma exposure after itraconazole treatment.

The study also observed increases in endocannabinoid-related metabolites: linoleoyl ethanolamide and N-linoleoylglycine rose 2.4- to 6.0-fold. These findings concern endogenous compounds and CYP3A inhibition; the study did not test cannabis or cannabinoid treatment. In vitro work supported a mechanistic link between CYP3A4 and GHCA formation. This is an abstract-based summary: the small healthy-volunteer study and evaluation of one inhibitor cannot establish how well these markers perform across other CYP3A inhibitors or in broader clinical settings.

πŸ’‘ Key Findings

1
In 11 healthy volunteers, itraconazole treatment was associated with significant changes in 58 plasma metabolites.
High
90%
2
GHCA, GUDCA, and 1Ξ²OH-DCA conjugates showed roughly 10-fold lower plasma exposure after itraconazole treatment.
High
90%
3
Endocannabinoid-related metabolites linoleoyl ethanolamide and N-linoleoylglycine increased 2.4- to 6.0-fold following itraconazole treatment.
High
90%
4
In vitro findings showed CYP3A4-selective hydroxylation of glycochenodeoxycholate to form GHCA, supporting GHCA as a mechanistically linked marker of CYP3A4 activity.
High
85%

πŸ“„ Original Abstract

Reliable endogenous biomarkers for assessing CYP3A activity and clinical drug-drug interaction (DDI) risk remain limited. We characterized global metabolomic changes following itraconazole treatment in a fixed-sequence DDI study (11 healthy volunteers) to identify novel CYP3A endogenous biomarkers. Untargeted metabolomic analysis identified 58 plasma metabolites that were significantly modulated (changed by > 1.5-fold or < 0.67-fold, P < 0.05), highlighting the dynamic and systemic impact of CYP3A inhibition on the human metabolome. Bile acids represented the most prominently affected analytes, whereas changes were also observed in endocannabinoids, xanthine metabolism, and food-derived metabolites, revealing both on-target and potential off-target effects of itraconazole. For example, plasma levels of endocannabinoidome metabolites such as linoleoyl ethanolamide and N-linoleoylglycine increased by 2.4- to 6.0-fold (P < 0.05), while bile acids including glycoursodeoxycholate (GUDCA) and glycohyocholate (GHCA) decreased by 2.6- to 12.5-fold (P < 0.01) following itraconazole treatment. Targeted quantification was subsequently performed for the bile acids identified from untargeted analysis and the emerging CYP3A biomarkers, 1Ξ²-hydroxy-deoxycholic acid (1Ξ²OH-DCA) and its glycine and taurine conjugates. Notably, GHCA, GUDCA and 1Ξ²OH-DCA conjugates exhibited pronounced reduction in plasma exposure (~10-fold, P < 0.001) in the itraconazole treatment group. GHCA exhibited lower inter-individual variability than others. InΒ vitro characterization demonstrated CYP3A4-selective hydroxylation of glycochenodeoxycholate to form GHCA, supporting its mechanistic linkage to CYP3A4 activity. Collectively, these findings expand the repertoire of sensitive and mechanistically supported endogenous biomarkers of CYP3A activity. Further evaluation of the newly identified GHCA and emerging bile acid metabolites across diverse CYP3A inhibitors can strengthen their translational utility in DDI risk assessment and drug development.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.